Interní Med. 2007; 9(1): 14-18

Therapy of diastolic heart failure

prof. MUDr. Lenka ©pinarová Ph.D., FESC, prof. MUDr. Jindřich ©pinar CSc., FESC
I. interní kardioangiologická klinika FN u sv. Anny v Brně

Authors review current knowledge of treatment of diastolic heart failure. So far several smaller clinical trials were accomplished showing improvement of exercise tolerance after verapamil, betablockers, ACE-inhibitors and AII receptor antagonists. First three large mortality clinical trials-CHARM Preserve with candesartane, SENIORS with nebivolol and PEP-CHF with perindopril proved decrease number of hospitalisation, in mortality there is only a trend toward improvement. The essentials of treatment are further on good control of hypertension and heart rate. Basic medication groups are betablockers, ACE-inhibitors and AII receptor antagonists.

Keywords: Key words: diastolic failure, betablockers, ACE-inhibitors, AII receptor antagonists, hypertension.

Published: January 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
©pinarová L, ©pinar J. Therapy of diastolic heart failure. Interní Med. 2007;9(1):14-18.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Arronow WS, Athn C. Kronzon I. Effect of propranolol versus no propranolol on total mortality plus non fatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, ande left vetricular ejection fraction > or 40% treated with diuretics plus angiotensin converting enzyme. Am J Cardiol 1997; 80: 207-209. Go to original source... Go to PubMed...
    2. Arronow WS, Kronzon I. Effect of enalapril on congestive heart failure treated with diuretics in elderly patients with prior myocardial infarction and normal left ventricle ejection fraction. Am J Cardiol 1993; 71: 602-604. Go to original source... Go to PubMed...
    3. Cleland JGF, Tendera M, Adamus J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Hear J 2006; 27: 2338-2345. Go to original source... Go to PubMed...
    4. Dahlof B, Devereux RB, Kjeldsen SE for the LIFE investigators: Cardovascular morbidity and mortality in the losartan intervention for endpoints reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003. Go to original source... Go to PubMed...
    5. Flather MD, Shibata MC, Coats AJS, Van Veldhuisen DJ, Parkhomenko A, Borobla J, CohenSolal A, Dumitrascu D, Ferrari R, Lechat P, Soler-Soler J, Tavazzi L, Spinarova L, Toman J, Bohm M, Anker S, Thompson SG, Poole-Wilson PA. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26: 215-225. Go to original source... Go to PubMed...
    6. Gaasch WH, Zile MR. Left ventricular diastolic dysfunction and diastolic heart failure. Ann Rev Med 2004; 55: 373-394. Go to original source... Go to PubMed...
    7. Hradec J. Diastolické srdeční selhání. Diagnostika, epidemiologie, prognóza. Kardiologická revue 2004; 4: 156-160.
    8. Hung MJ, Chreng WJ, Kuo LT, Wang CH. Effect of verapamil in elderly patients with left ventricular diastolic dysfunction as a cause of congestive heart failure. Int J Clin Pract 2002; 56: 57-62. Go to original source... Go to PubMed...
    9. Pfeffer MA, McMurray JJV, Velazquez EJ, et al. for VALIANT Investigators: valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893-1906. Go to original source... Go to PubMed...
    10. Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the task force for the diagnosis and treatment of chronic heart failure of the european society of cardiology. Eur Heart J. 2005; 26: 1115-1140. Go to original source... Go to PubMed...
    11. ©pinar J, Hradec J, Málek I, Toman J. Doporučení pro diagnostiku a léčbu chronického srdečního selhání. Cor et Vasa 2001; 6 (43): K123-138.
    12. ©pinar J, Hradec J, Lupínek P, et al. Doporučení pro diagnostiku a léčbu chronického srdečního selhání-guidelines ČKS 2006. Přijato k publikaci Cor et Vasa 2007.
    13. The DIG investigators: The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336: 525-533. Go to original source... Go to PubMed...
    14. The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-contolled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-788.
    15. Widimský P. Studie EUROPA: Úspěch perindoprilu a české kardiologie. Cor et Vasa 2004; 46: 7-8.
    16. Yusuf S, Pfeffer MA, Swedberg K, et al: Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362: 777-781. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.